¹Ø×¢×ðÁú¿Ê±Medicilon¹«Öںţ¬ÔÚÖ÷ҳ̸Ìì¿ò»Ø¸´¡°ÊµÑ鱨¸æ¡±£¬¼´¿ÉÉó²é¡°Ä³Ä¿µÄÂѰ×PROTAC-POIÌåÍâɸѡ¡±µÄÏêϸʵÑ鱨¸æ£¡

PROTACÊÖÒÕ×÷ÓûúÖÆÆæÒì

1.PROTAC·Ö×Óͨ¹ýÆäÒ»¶ËµÄ°ÐÂѰ×ÅäÌ壨POI Ligand£©ÌØÒìÐÔʶ±ð²¢Á¬Ïµ°ÐÂѰף¬Í¨¹ýÆäÁíÒ»¶ËµÄE3·ºËØÅþÁ¬Ã¸ÅäÌ壨E3 Ligase Ligand£©ÌØÒìÐÔʶ±ð²¢Á¬ÏµE3 Ligase£»
2.ÐγÉP O I - P R O T A C - E 3ligaseÈýÔª¸´ºÏÌ壻
3.ÔÚ´ËÈýÔª¸´ºÏÌåÖУ¬°ÐÂѰ×POI±»E3 ligase·ºËØ»¯ÐÞÊΣ¬·ºËØ»¯ÐÞÊÎÁ˵ÄPOIËæºó±»ÂѰ×øÌåʶ±ð²¢½µ½â£¬ÓÉ´ËÒÖÖÆ°ÐÂѰ׵Ĺ¦Ð§
PROTACÊÖÒÕÔÚÒ©ÎïÑз¢·½ÃæµÄÓÅÊÆ
¸Ä±ä°ÐµãµÄ¡°²»¿É³ÉÒ©ÐÔ¡±£¨undruggable£©
PROTACµÄ×÷Ó÷Ö×Ó»úÖÆÊÇͨ¹ý·ºËØ-ÂѰ×øϵһÇнµ½â°ÐÂѰף¬²¢·Çͨ¹ý¾ºÕùÁ¬ÏµÒԹرհÐÂѰ׹¦Ð§Çø¶øÊ©Õ¹ÂѰ׹¦Ð§ÒÖÖÆ×÷Óã¬Òò´ËPROTAC¶Ô°ÐÂѰ×ʶ±ðÁ¬ÏµÇø·×Æç¶¨·ÇµÃÊÇ»îÐÔÇø£¬½áÐÁ¦Ò²·×Æç¶¨±ØÐèÊǸßÇ׺ÍÁ¦£»ÕâʹµÃһЩȱ·¦¸ßÇ׺ÍÁ¦Ð¡·Ö×ÓÁ¬ÏµµÄ¡°²»¿É³ÉÒ©ÐÔ¡±°ÐÂѰ×Äð³É¡°¿É³ÉÒ©ÐÔ¡±;
¸ßЧÐÔ
¹Å°åС·Ö×ÓÒÖÖÆ¼Áͨ¹ý¾ºÕùÁ¬Ïµ°ÐÂѰ׻îÐÔ¹¦Ð§Óò¶øÒÖÖÆ°ÐÂѰ׹¦Ð§£¬ËùÐèС·Ö×ÓµÄÁ¿ÍùÍù½Ï´ó£»¶øPROTACͨ¹ý·ºËØ-ÂѰ×øϵһÇнµ½â°ÐÂѰ×ÒÔɨ³ý°ÐÂѰ׹¦Ð§£¬¹Ê¾ßÓпÉÑ»·Ê¹ÓÃÐÔ¡¢ÓÃÁ¿µÍºÍ¸ßЧÐÔµÄÌØµã¡£
ÎÞÃâÒßÔÐÔ
Ó뿹ÌåÒ©ÎïÏà±È£¬PROTAC²»»áÒý·¢¿¹Ò©¿¹Ì屬·¢¡£
×ÛÉÏ£¬PROTACÒѳÉΪҩÎïÑз¢ÁìÓòµÄÐÂÐËÀûÆ÷£¬ÔÚº£ÄÚÍⱸÊÜ¿ÆÑе¥Î»¼°Ò©ÆóËù×·Åõ¡£
×ðÁú¿Ê±PROTACÊÖÒÕЧÀÍÏÈÈÝ
°Ð±êÂѰ×PROTAC-POIµÄÉè¼ÆºÏ³É
×ðÁú¿Ê±»ã×ÜÁËÄ¿½ñÊ¢ÐеÄÈÈÃÅPOIÅäÌ壬²î±ð×éÖ¯ÀàÐ͵ÄE3ligaseÅäÌ壬²¢ÇÒ½¨ÉèÁ˺¬Êý°ÙÖÖÅþÁ¬·Ö×ÓµÄlinker¿â¡£
±ðµÄ£¬×ðÁú¿Ê±³ÉÊìµÄÅÌËã»ú¸¨ÖúÒ©ÎïÉè¼ÆÊÖÒÕÆ½Ì¨£¬´ó´óÌá¸ßPROTAC-POIµÄÉè¼ÆºÏ³ÉÖÊÁ¿¡£
PROTAC-POIµÄÌåÍâɸѡ
HEK 293TÎÈתÖêϸ°û£¨POI-EGFP£©¸ßͨÁ¿É¸Ñ¡
ʹÓûùÒòÇÃÈëÊÖÒÕ¹¹½¨µÄ¡°ÄÚÔ´ÂѰ×-EGFP¡±293TÎÈתÖêϸ°û£¬¶ÔPROTAC·Ö×Ó¾ÙÐиßͨÁ¿É¸Ñ¡£¬ÅÌËãDC50¡£

Percentage reduction in POI-EGFP fusion protein level
Western Blot£¨WB£©
ͨ¹ýWBʵÑé¼ì²â³õɸµ½µÄPROTAC·Ö×Ӷ԰бêÂѰ׵Ľµ½âÄÜÁ¦£¬ÆÊÎöDC50Öµ¡£

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI
ϸ°û¶¾ÐÔʵÑ飨CCK-8»òCTG·¨£©
¼ì²âÉÏÊöɸѡµ½PROTC-POI¶Ô°©Ï¸°ûÔöÖ³ÒÖÖÆÄÜÁ¦£¬ÆÊÎöIC50Öµ¡£
»úÖÆ¼ì²â
a. ¼ì²âPROTACÊÇ·ñͨ¹ýE3 CRBN¶Ô°ÐÂѰ׾ÙÐнµ½â¡£

Fig. 2 Western Blot Images showing POI degradation by PROTAC-POI
b. ÌØÒìÐÔ¼ì²â£ºÍ¨¹ýʹÓÃLC-MS/MS¾ÙÐÐÂѰ××éѧÆÊÎö£¬È·¶¨PROTAC½µ½âÂѰ׵ÄÌØÒìÐÔ£»Ê¹ÓÃKINOMEscanÆÊÎöPROTAC¶Ô¼¤Ã¸Á¬ÏµµÄÌØÒìÐÔ¡£

Proteasome system mediates PROTAC-POI-induced POI Degradation
Ö×Áöϸ°ûµÄÔöÖ³ÒÖÖÆÐ§Ó¦
ʹÓÃCCK-8»òCTG·¨£¬¼ì²âPROTAC¶ÔÖ×Áöϸ°ûµÄÔöÖ³ÒÖÖÆÐ§¹û¡£

Proliferation inhibition effects of POI in the indicated cell lines at 120 h after treatment
PROTAC-POIµÄ¶¯ÎïÌåÄÚҩЧɸѡ
CDXСÊóÖ×ÁöÄ£×Ó
½«ÏìÓ¦°©ÖÖϸ°ûÏµÒÆÖ²µ½ÂãÊó»òNSGСÊóÌåÄÚ£¬½¨ÉèÆ¤ÏÂÁö»òÔλÁöÄ£×Ó£¬Í¨¹ý¿Ú·þ¡¢¹àθ»ò¾²Âö¸øÒ©£¬¼ì²âÌåÍâɸµ½µÄPROTAC-POI¶ÔÊóÌåÄÚÖ×ÁöÉú³¤µÄÒÖÖÆÐ§¹û¡£

PDXСÊóÖ×ÁöÄ£×Ó
½«Ö×Áö×éÖ¯ÒÔ×éÖ¯¿éµÄÐÎÊ½ÒÆÖ²µ½NSGСÊóÌåÄÚ£¬ÕâЩÖ×Áö×éÖ¯ÔÚNSGСÊóÌåÄÚ¼á³ÖÁËÔʼÖ×ÁöµÄÉúÎïÑ§ÌØÕ÷£¬ÓëÁÙ´²ÌØÕ÷ÏàËÆ¶È¸ü¸ß¡£Ê¹ÓÃPDXСÊóÄ£×Ó¼ì²âPROTAC-POI¶ÔÌåÄÚÖ×ÁöÉú³¤µÄÒÖÖÆÐ§¹û¡£

PK/PDÑо¿¡¢Ò©Ñ§ÆÊÎö¡¢Ò©Îï´úл¶¯Á¦Ñ§Ñо¿ºÍÇå¾²ÐÔÆÀ¼Û
¶Ô¶¯ÎïÌåÄÚҩЧ¼ì²âɸѡ»ñµÃµÄÀíÏëµÄPROTAC-POI¾ÙÐÐPK/PDÑо¿¡¢Ò©Ñ§ÆÊÎö¡¢Ò©Îï´úл¶¯Á¦Ñ§Ñо¿ºÍÇå¾²ÐÔÆÀ¼Û£¬²¢»ã×ÜʵÑéЧ¹ûºÍÖÊÁϾÙÐÐINDÉ걨£¬ÒÔÖúÁ¦¿Í»§¼ÓËÙPROTAC-POIÒ©ÎïµÄÑз¢Àú³Ì¡£
ɨÃèÏ·½¶þάÂ룬¹Ø×¢×ðÁú¿Ê±Medicilon¹«Öںţ¬ÔÚÖ÷ҳ̸Ìì¿ò»Ø¸´¡°ÊµÑ鱨¸æ¡±£¬¼´¿ÉÉó²é¡°Ä³Ä¿µÄÂѰ×PROTAC-POIÌåÍâɸѡ¡±µÄÏêϸʵÑ鱨¸æ£¡

ÁªÏµ×ðÁú¿Ê±
Email: marketing@medicilon.com.cn
µç»°: +86 (21) 5859-1500£¨×Ü»ú£©